SEOUL — GI-Cell, a South Korean developer of immune cell therapy products, has partnered with DNA and protein-based therapeutics companies to jointly develop cell therapy technologies involving immune cells to enhance disease-fighting abilities of target patients.
GI-Cell has signed a memorandum of understanding with Helixmith and Cartexell to develop cell therapy medicine based on an immune cell expander platform. GI-Cell hopes to target the global immune cell therapy market through collaboration.
“We will do our best to come up with successful achievements in the cell therapy sector through collaboration with Helixmith and Catexell with full experience, technology, and manpower,” GI-Cell CEO Hong Chun-pyo said in a statement on April 28.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.